Elafibranor Therapy for PBC and PSC With Persistent Liver Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cholestatic diseases, particularly Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), such as Ursodeoxycholic acid (UDCA), are ineffective for a significant portion of patients, leading to high risks of cirrhosis, liver insufficiency, and the need for liver transplantation.
Innovation Solution
The use of Elafibranor, a compound administered at doses ranging from 0.01 mg to 1 g, preferably 70 to 130 mg, to treat cholestatic diseases, including PBC and PSC, by reducing biochemical markers and improving liver enzyme levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ursodeoxycholic acid (UDCA) is used to treat cholestatic diseases, then some patients experience therapeutic benefit, but a significant portion of patients show inadequate response leading to disease progression
Solution Approach 1:
The patent applies parameter changes by switching from UDCA to Elafibranor, which has a different mechanism of action (PPAR alpha/delta agonist vs. bile acid derivative). This chemical parameter change in the therapeutic agent resolves the contradiction by providing effective treatment for patients who do not respond to UDCA, thereby improving overall treatment reliability while reducing response variability.
2Reliability
If current standard treatments are used, then some liver function markers improve, but biochemical markers such as alkaline phosphatase and gamma-glutamyltransferase remain elevated in many patients
Solution Approach 1:
The patent employs parameter changes by introducing Elafibranor, a PPAR alpha/delta dual agonist, which simultaneously addresses multiple biochemical parameters. Clinical data in the patent demonstrates that Elafibranor effectively reduces alkaline phosphatase and gamma-glutamyltransferase levels while improving liver function, thereby resolving the contradiction between partial liver function improvement and persistent elevation of biochemical markers.
3Reliability
If Elafibranor is administered at high doses to maximize therapeutic effect, then biochemical markers are reduced more effectively, but potential side effects and toxicity increase
Solution Approach 1:
The patent optimizes the dosage parameter of Elafibranor to achieve therapeutic efficacy while minimizing toxicity. The specified dose range of 70-130 mg daily represents an optimized parameter that balances marker reduction effectiveness with safety, avoiding the harmful effects of higher doses while maintaining reliable therapeutic benefit.
Data Source
AI summary
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.